China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment along with intranasal corticosteroids to treat CRSwNP.
The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment along with intranasal corticosteroids to treat CRSwNP.
What's Your Reaction?
